

# Variants


*position and possible consequences*

*everything what can go wrong, will go wrong*

*[tinyurl.com/Avans201904b](https://tinyurl.com/Avans201904b)*

*Johan den Dunnen*

*based on lecture Jan Traeger-Synodinos  
VEPTC Prague 2017*



# Human & Clinical Genetics

( Leiden University Medical Center )

- Genetic Disease

*neuromuscular disorders*

*[http:// www.DMD.nl](http://www.DMD.nl)*

*diagnosis*

*treatment / therapy*

*exon skipping DMD*



- Genome Technology

*try and apply*

*facilitate*

*Leiden Genome Technology Center*

*[http:// www.LGTC.nl /](http://www.LGTC.nl/)*
















# My CV

## 1,000,000,000 molecules

## only DNA



## 1 molecule




# Subjects

---

## Variants

- *basic types*



## All possibilities & examples

- *DNA*
- *RNA*
- *protein*



*everything what can go wrong, will go wrong*

## Use your imagination

*which variants did you find / can you think of?*

# Variant < > phenotype

---

- combination should make sense

*gene function should “explain” phenotype*  
*gene expressed in affected tissue*  
*for analysis use affected tissue*  
*RNA, protein analysis*

- do not give up

*check options you can not exclude*  
*did you detect ALL possible variants*  
*did you consider all variant to problem options*



# Terminology

- prevent confusion

*mutation meaning, ...*

*-biology: change*

*-medical: disease-causing change*

*polymorphism, meaning ...*

*-biology: change in >1% population*

*-medical: not disease causing change*

- use neutral terms

*sequence variant*

*alteration*

**CNV** (Copy Number Variant)

**SNV** (not SNP)



*would you like to be a mutant?*

# Variant types ?

---

# Variant types ?

---

- error in sequence
- too much / too little
- wrong position  
*place, time*




# Variant types



- change in sequence

ACATCAGGAGAAGATGTTC	GAGACTTTGCCA
ACATCAGGAGAAGATGTT <b>T</b>	GAGACTTTGCCA
ACATCAGGAGAAGATGTT	GAGACTTTGCCA
ACATCAGGAGAAGATGTTC <b>C</b>	GAGACTTTGCCA

- change in amount *(Copy Number Variation)*



- change in position



Structural Variation (SV)

# Variants

---

- small changes  
...
- larger changes  
...

# Variants

---

- **small changes**  
*substitution*  
*few nucleotide changes*

*deletion, duplication, insertion, “indel”*

- **larger changes**  
*structural variants (SV)*

*translocation*

*insertion*

*transposition*

*copy number variant (CNV)*

*deletion*

*duplication (insertion)*

*inversion*

*conversion*


*complex*

*protein coding variant*  
*“easy” to explain, others*  
*often difficult to proof*

# MILPA result

- result of an MLPA  
*what did the assay detect ?*

*the assay detects an extra copy  
where the extra copy is remains to be  
determined, could be anywhere in the genome*



***some genes are dosage sensitive, some are not***  
*deletions are more likely to be deleterious than duplications*  
*determining the exact break point is critical (incl. RNA analysis)*  
*the amount of product can also be deleterious*

# Origin of variants

- **during cell cycle**

***DNA replication*** (copying information)

***meiosis / mitosis*** (dividing information)

***different rates in female / male***

***large rearrangements / SNVs***

- **damage**

***environmental***

***radiation, chemicals (smoke), UV, ...***

***~100,000 per cell daily***

***consequence?***

<b>Germline (inherited)</b>	<b>Somatic (acquired)</b>
<i>present from birth</i>	<i>acquired during life</i>
<i>present in every cell</i>	<i>limited to certain cells</i>
<i>can be transmitted</i>	<i>non transmitted</i>



# De novo variants

- genome sequencing  
*78 mother-father-child trios*

- de novo variants  
*~60 small scale changes*

*~15 maternal  
~45 paternal*

*stable over time  
variable with age*

- effect paternal age  
*20y > 25 variants  
40y > 65 variants  
2 extra variants / year*




## ARTICLE

23 AUGUST 2012 | VOL. 488 | NATURE 471

### Rate of *de novo* mutations and the importance of father's age to disease risk

Augustine Kong<sup>1</sup>, Michael L. Frigge<sup>1</sup>, Gisli Masson<sup>1</sup>, Soren Besenbacher<sup>1,2</sup>, Patrick Salem<sup>1</sup>, Gisli Magnusson<sup>1</sup>, Sigurjon A. Gudjonsson<sup>1</sup>, Asgeir Sigurdsson<sup>1</sup>, Aslaug Jonasdottir<sup>1</sup>, Adalbjorg Jonasdottir<sup>1</sup>, Wendy S. W. Wong<sup>3</sup>, Gunnar Sigurdsson<sup>1</sup>, G. Bragi Walters<sup>1</sup>, Stacy Steinberg<sup>1</sup>, Hannes Helgason<sup>1</sup>, Gudmar Thorleifsson<sup>1</sup>, Daniel F. Gudbjartsson<sup>1</sup>, Agnar Helgason<sup>1,4</sup>, Olafur Th. Magnusson<sup>1</sup>, Unnur Thorsteinsdottir<sup>1,5</sup> & Kari Stefansson<sup>1,6</sup>

*Kong et al. 2012 Nature 488: 471*



# How many

based on 1000 Genomes Project Consortium

- 4.1-5.0 million small changes

*SNVs, short indels*

- 2,100-2,500 other variants

*1,000 large deletions*

*160 CNVs*


*915 Alu / 128 L1 insertions*

*51 composite SINE/VNTR/Alu insertions*

*4 nuclear mitochondrial DNA variants*

*10 inversions*

( includes upto 30 Mb's of sequence present in you not your neighbour )




# Long-read sequencing

<http://www.pacb.com/wp-content/uploads/2017-EMEA-UGM-A-Hoischen-Long-read-Sequencing.pdf>


A. Hoischen (Nijmegen)

Radboudumc



*small SVs*

*~25,000 SVs per genome*



*large SVs*

*Modern approach*

*sequence, everything!*



# NGS: one fits all ?

---

- NGS fails to detect...




# NGS: one fits all ?

---

- **targeted assays remain valuable**  
*clear cause: cost effective direct assay*  
*why sequence everything?*  
*protein coding variants "easy", others difficult to proof*
- **NGS fails to detect**  
*most structural variants (SV)*  
*incl. deletions / duplications*  
*variants in repeated/variable length sequences*  
*MUC genes*  
*variants in highly variable regions*  
*HLA*  
*repeat expansions*  
*trinucleotide expansions*  
*rearrangements covering more than read length*

# Repeat expansions



*unmapped  
too many mismatches*

Reference genome 5'-GTT CAT-(TTT TA)<sub>7</sub> TTA(TTT TA)<sub>13</sub>-TTT GA

F6906 (II-6) 5'-GTT CAT-(TTT TA)<sub>2</sub> TTT TTT TA(TTT TA)<sub>104</sub> TTT A(TTT TA)<sub>3</sub> TTT A(TTT TA)<sub>10</sub> (TTT CA)<sub>66</sub>-TTT GA

F6115 (I-2) 5'-GTT CAT-(TTT TA)<sub>3</sub> TTT TTT TTA(TTT TA)<sub>60</sub> (TTT CA)<sub>61</sub> (TTT TA)<sub>73</sub> TTT ATT TTT A-TTT GA

nature  
genetics

ARTICLES

<https://doi.org/10.1038/s41588-018-0067-2>

## Expansions of intronic TTTCA and TTTTA repeats in benign adult familial myoclonic epilepsy

Hiroyuki Ishiura<sup>1</sup>, Koichiro Doi<sup>2</sup>, Jun Mitsui<sup>1</sup>, Jun Yoshimura<sup>2</sup>, Miho Kawabe Matsukawa<sup>1</sup>, Asao Fujiyama<sup>3</sup>, Yasuko Toyoshima<sup>4</sup>, Akiyoshi Kakita<sup>4</sup>, Hitoshi Takahashi<sup>4</sup>, Yutaka Suzuki<sup>5</sup>, Sumio Sugano<sup>6</sup>, Wei Ou<sup>2</sup>, Kazuki Ichikawa<sup>2</sup>, Hideaki Yurino<sup>2</sup>, Koichiro Higasa<sup>8</sup>, Shota Shibata<sup>1</sup>

# Human genome

version 27 (Jan.2017, freeze hg38)  
- Ensembl 90




- 58,288 genes


19,836 protein coding  
15,788 long non-coding RNA  
7,269 small non-coding RNA  
14,694 pseudogenes  
644 immunoglobulin / T-cell receptor gene segments

5-10% genes is present in multiple copies

not all genes are critical




# Information



# Translation variants


- **silent**  
*no amino acid change*
- **substitution**  
*amino acids changes to another amino acid*
- **nonsense**  
*amino acids changes to stop codon*
- **frame shift**  
*translation shifts to another reading frame change*
- **in-frame**  
*deletion, duplication, insertion*
- **other**  
*extension (upstream initiation, no stop),  
ATG codon, ...*






# Transcription

*a gene*




*required ?*

*a transcript*



# Transcription

*a gene*



*promoter*

*transcription initiation site (cap site)*

*transcription termination*


*polyA-addition site, polyA-addition signal*

*splice donor / splice acceptor site*

*exonic splice enhancer / silencer (ESE / ESS)*

*intronic splice enhancer / silencer (ISE / ISS)*


...



Scotti & Swanson, Nat.Rev.Genet. 2016


# Consequences: RNA

*globin genes*  
(see *HbVar* for details)




# Translation

*mRNA*



*required ?*




*protein*



<http://ib.bioninja.com.au/higher-level/topic-7-nucleic-acids/73-translation/protein-structure.html>

# Translation

*mRNA*



*translation initiation site*

*(start codon, Kozak sequence)*

*translation termination site (stop codon)*

*uORF*



*codon usage > translation speed > protein folding*

*RNA/protein binding > stability, amount of protein*

*...*



# uORF



*Human Molecular Genetics*, 2015, Vol. 24, No. 4 899–912  
doi:10.1093/hmg/ddu501  
Advance Access published on September 30, 2014

***CFTR* mRNA expression is regulated by an upstream open reading frame and RNA secondary structure in its 5' untranslated region**

Samuel W. Lukowski<sup>1,2,†,\*</sup>, Joseph A. Rothnagel<sup>1</sup> and Ann E. O. Trezise<sup>1,2</sup>

influence process > increase protein expression

> treat CF-patients

# Consequences: protein

---

- others signals present in protein?

# Consequences: protein

---

- **sequence**
  - activity - enzymes*
  - cleavage sites - to mature protein*  
*(cell export/import)*
  - domains, signals - NLS*
  - modification - phosphorylation, S-S bridges, glycosylation*
- **protein folding**
  - secondary, tertiary, protein-protein interaction*
- **amount**
  - too much / little*
  - stability (protein turnover)*    degradation speed of protein
- ...


# ...expression

---


- **place**  
*expression in wrong tissue*
- **timing**  
*expression at the wrong time*  
*during development*  
*responding to incorrect trigger*
- ...

# T-sensitive

30°C



37°C



40°C



HUMAN MUTATION 24:130–139 (2004)

## RESEARCH ARTICLE

Identification of the Molecular Defect in Patients With Peroxisomal Mosaicism Using a Novel Method Involving Culturing of Cells at 40°C: Implications for Other Inborn Errors of Metabolism

Jeannette Gootjes,<sup>1</sup> Frank Schmohl,<sup>1</sup> Petra A.W. Mooijer,<sup>2</sup> Conny Dekker,<sup>2</sup> Hanna Mandel,<sup>3</sup> Meral Topcu,<sup>4</sup> Martina Huemer,<sup>5</sup> M. von Schütz,<sup>6</sup> Thorsten Marquardt,<sup>7</sup> Jan A. Smeitink,<sup>8</sup> Hans R. Waterham,<sup>2</sup> and Ronald J.A. Wanders<sup>1,2\*</sup>

*low T: dampens*  
*high T: exaggerates*

temperature change impacts slicing



# Consequences: DNA

---

- signals present in DNA?  
*destroyed or created*


# Consequences: DNA

---

- replication origin
- TAD  
*topologically active domain (expression control)*
- expression  
*enhancer (LCR), transcription factor binding, ...*
- protein binding  
*required for any process*
- DNA modification (*methylation*)  
*X-inactivation, imprinting, gene expression*
- ...  
...

# LCR

- expression  
*LCR - locus control region*  
*regulatory elements often kb's to sometimes Mb's upstream*



Higgs, Cambridge University Press (2009)


HBA gene cluster

# New promoter

- expression

- new promoter*

*SNV creates TFB site, activating transcription, silencing downstream genes*




*HBA  
genes*

De Gobbi, Science (2006) 312:1215

# Indirect silencing

- **expression**  
**gene silencing**  
*read-through silences downstream gene*

Ligtenberg, Nature Genet. (2009) 41:112.



*EPCAM gene*

*MSH2 gene*

deletion 3'end EPCAM > transcription continues into MSH2

*fusion transcript (out-frame), silencing MSH2 promoter > no MSH2*




# Non-coding genes

- variants in non-coding genes  
*probably many still unknown*

Genomic Element	Name	Disorder
MIR	MIR96	DFNA50 (Autosomal Dominant deafness 50)
	MIR184	EDICT syndrome
	MIR17HG	Feingold syndrome 2
Long ncRNA	TERC	AD dyskeratosis congenita; susceptibility to aplastic anemia
	RMRP	CHH (cartilage hair hypoplasia) syndrome; anauxetic dysplasia; metaphyseal dysplasia without hypotrichosis
	CISTR-ACT lncRNA	Type E polydactyly
	HELLP lincRNA	HELLP (Hemolysis, Elevated Liver enzymes, Low Platelets) syndrome
Small ncRNA	ATXN8/ATXN8OS	Spinocerebellar ataxia 8 (SCA8)
	snRNA RNU4ATAC	Microcephalic Osteodysplastic Primordial Dwarfism, type I (MOPD I)

*Makrythanasis and Antonarakis, Clin.Genet. (2013)*

# Where to find



*conservation,  
activity*

+	Mapping and Sequencing
+	Genes and Gene Predictions
+	Phenotype and Literature
+	mRNA and EST
+	Expression
+	Regulation
+	Comparative Genomics
+	Neandertal Assembly and Analysis
+	Denisova Assembly and Analysis
+	Variation
-	Repeats

# Listing variants

- **be specific**

*list per level: DNA, RNA, protein*

*where to list a DNA substitution,  
altering RNA splicing (insertion),  
resulting in a frame shift*

- **SO**

## **DNA**

*substitution, deletion, duplication, insertion, delins, inversion, ...  
(large deletion, duplication, insertion, ...)*

## **RNA**



*substitution, deletion, duplication, insertion, delins, ...  
(splice deletion or insertion)*

## **protein**

*missense, nonsense, frame shift, in frame, deletion / duplication /  
insertion / delins*

# Female DMD


- **muscle biopsy**  
*no dystrophin staining*
- **MLPA**  
*deletion exons 48-53*  
*in-frame*
- **sequencing**  
*no deleterious variants*
- **X-inactivation**  
*random*



**please explain**



*Is my  
conclusion  
right ?*






# Female DMD

- RNA analysis

## RNA analysis



Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

**ScienceDirect**

Neuromuscular Disorders 27 (2017) 569–573


Case report

**Duchenne muscular dystrophy in a female with compound heterozygous contiguous exon deletions**

Eri Takeshita <sup>a,\*</sup>, Narihiro Minami <sup>b,c</sup>, Kumiko Minami <sup>c</sup>, Mikiya Suzuki <sup>d</sup>, Takeya Awashima <sup>a</sup>, Akihiko Ishiyama <sup>a</sup>, Hirofumi Komaki <sup>a</sup>, Ichizo Nishino <sup>c,e</sup>, Masayuki Sasaki <sup>a</sup>

<sup>a</sup> Department of Clinical Neurophysiology, National Institute of Advanced Industrial Science and Technology, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8565, Japan; <sup>b</sup> Department of Clinical Neurophysiology, National Institute of Advanced Industrial Science and Technology, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8565, Japan; <sup>c</sup> Department of Clinical Neurophysiology, National Institute of Advanced Industrial Science and Technology, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8565, Japan; <sup>d</sup> Department of Clinical Neurophysiology, National Institute of Advanced Industrial Science and Technology, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8565, Japan; <sup>e</sup> Department of Clinical Neurophysiology, National Institute of Advanced Industrial Science and Technology, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8565, Japan

*two different deletions,  
both frame shifting*



# Your example

---



...

# Acknowledgement

---

*Presentation prepared by:*

*Johan den Dunnen*

*Human Genetics & Clinical Genetics  
Leiden University Medical Center  
Leiden, Nederland*



*date: April 2019*

*based on lecture Jan Traeger-Synodinos  
VEPTC Prague 2017*